GlassScriptPhysician profile
John F Mattei
NPI 1316959687
$14,564.48
in general payments reported to CMS, 2019-2025
64 companies · $1,981 in 2025
The $1,981 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,799 · 2020: $1,650 · 2021: $2,634 · 2022: $2,044 · 2023: $2,762 · 2024: $1,695 · 2025: $1,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,342 · Education: $95.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,342.12 |
| Education | $95.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,440.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,288.80 | 2021-2025 | |
| Pfizer INC. | $1,264.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,184.63 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Kowa Pharmaceuticals America, INC. | $730.99 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Amgen INC. | $690.84 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $657.86 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $631.25 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $557.13 | 2019-2024 | Jardiance |
| Abbott Laboratories | $532.55 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $463.28 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $443.48 | 2022-2025 | |
| Azurity Pharmaceuticals, INC. | $384.21 | 2023-2025 | Horizant, Horizant, Alvesco |
| Amarin Pharma, INC. | $356.95 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $283.17 | 2020-2025 | Verquvo, Belsomra, Capvaxive |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mattei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.